Product Reports Resources Pricing Login Book a demo

BioMarin Pharmaceutical

Biotech & Life Sciences · San Rafael, United States · Founded 1997 · IPO 1999

Developing innovative therapies targeting rare genetic diseases

Valuation $11B
Revenue $3.87B
EBITDA $573M

Talent graph

BioMarin Pharmaceutical's talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 10 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Investors

3 investors on BioMarin Pharmaceutical's cap table

Sourced from Dealroom's funding and investor records.

Series A 3 investors entered at this stage
Clubb Capital
BBB
Genzyme

Global footprint

Where BioMarin Pharmaceutical has talent and traffic

Workforce by country
🇺🇸 United States · San Rafael HQ
Book a demo for the full country breakdown

Patent intelligence

$457M patent portfolio · 218 active families

Estimated portfolio value
$457M
4.2% of market cap · 4.6× larger than top peer Dicerna Pharmaceuticals ($100M)
218 active patent families
Where BioMarin Pharmaceutical innovates BiochemistryDiseaseDisease injuryEnzymeLysosome

Where BioMarin Pharmaceutical concentrates vs peers

Each axis is a top-10 topic across BioMarin Pharmaceutical and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

BioMarin Pharmaceutical's 6 investments and acquisitions.

Every disclosed deal where BioMarin Pharmaceutical appeared as a backer or acquirer, 2010–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across BioMarin Pharmaceutical's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        BioMarin Pharmaceutical's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        What the market is saying about BioMarin Pharmaceutical

        An AI-synthesized read of the highest-engagement posts about BioMarin Pharmaceutical on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See BioMarin Pharmaceutical on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.